Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: End2War who wrote (1059)	5/30/2025 2:54:22 PM
From: bobbseytwins2001	Read Replies (2) \| Respond to of 1229

End2War, Thank you for the first explanations that make some sense to us. The explanation that these are not "directional" trades would explain what appears on the surface to be aggressive short selling, which makes no sense, because the risks of being wrong are potentially astronomical. The convertible debt explanation seems a logical start to understanding this possible arbitrage. We are now somewhat reassured that the fundamentals are still intact, and adding more shares as they continue to improve, especially sales, seems a good strategy. Of course if for any reason IBRX starts a run, short covering will be a huge bonus for longs. We are guessing that something like this happened a few years ago when IBRX exploded to $45+, and then cratered.